INV-102
Stimulant Use Disorder
Key Facts
About Indivior
Indivior is a publicly traded, revenue-generating biopharmaceutical company dedicated to addressing substance use disorders and serious mental illnesses. A pioneer in addiction medicine, its strategy is anchored by its market-leading SUBLOCADE® (monthly buprenorphine injection) and a pipeline extending its long-acting platform into schizophrenia and depression. The company faces significant risks from ongoing legal liabilities, generic competition, and pipeline execution, but its U.S. relocation, focused commercial execution, and potential new product launches provide a pathway for sustained growth in a critical therapeutic area.
View full company profileAbout Invirsa
Invirsa is a private, clinical-stage biotech leveraging a novel DNA damage response (DDR) platform centered on its lead compound, INV-102. The company has secured significant non-dilutive funding from BARDA and is advancing parallel development for ocular chemical injury (a medical countermeasure) and the large commercial market of diabetic dry eye. With a completed Phase 2 trial and a seasoned leadership team, Invirsa is positioned to validate its platform across multiple indications with high unmet need.
View full company profileAbout Invirsa
Invirsa is a private, clinical-stage biotech leveraging a novel DNA damage response (DDR) platform centered on its lead compound, INV-102. The company has secured significant non-dilutive funding from BARDA and is advancing parallel development for ocular chemical injury (a medical countermeasure) and the large commercial market of diabetic dry eye. With a completed Phase 2 trial and a seasoned leadership team, Invirsa is positioned to validate its platform across multiple indications with high unmet need.
View full company profileAbout Invirsa
Invirsa is a private, clinical-stage biotech leveraging a novel DNA damage response (DDR) platform centered on its lead compound, INV-102. The company has secured significant non-dilutive funding from BARDA and is advancing parallel development for ocular chemical injury (a medical countermeasure) and the large commercial market of diabetic dry eye. With a completed Phase 2 trial and a seasoned leadership team, Invirsa is positioned to validate its platform across multiple indications with high unmet need.
View full company profileTherapeutic Areas
Other Stimulant Use Disorder Drugs
| Drug | Company | Phase |
|---|---|---|
| Platform Expansion | Amygdala Neurosciences | Research |